Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

514
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
514
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

524
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
524
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

661
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Versus Late Initiation of Evolocumab and Arterial Aneurysm Events: An Analysis of FOURIER and FOURIER-OLE.

Circulation·2026
Same author

Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke.

Circulation·2025
Same author

The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-study.

European journal of preventive cardiology·2025
Same author

A missed opportunity: Incidental coronary artery calcification prior to acute coronary syndrome.

International journal of cardiology. Heart & vasculature·2025
Same author

The efficacy and safety of low dose colchicine in atherosclerotic cardiovascular disease: a systematic review and meta-analysis.

European journal of preventive cardiology·2025
Same author

Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.

Circulation·2025

Related Experiment Video

Updated: Jul 4, 2025

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

19.5K

Colchicine in atherosclerotic cardiovascular disease.

Bradley Tucker1,2, Neil Goonetilleke3, Sanjay Patel1,4

  • 1Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

Heart (British Cardiac Society)
|February 8, 2024
PubMed
Summary

Oral colchicine effectively reduces cardiovascular events by 25% but offers no survival benefit. Further research is needed to clarify its net risk-benefit profile for atherosclerotic vascular disease prevention.

Keywords:
Acute Coronary SyndromeAtherosclerosisCoronary Artery DiseaseInflammationStroke

More Related Videos

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.3K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.7K

Related Experiment Videos

Last Updated: Jul 4, 2025

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

19.5K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.3K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.7K

Area of Science:

  • Cardiology
  • Pharmacology
  • Inflammation Research

Background:

  • Atherosclerotic vascular disease is driven by inflammation.
  • Oral colchicine possesses anti-inflammatory properties with potential cardiovascular benefits.
  • Recent trials and meta-analyses evaluated colchicine's impact on cardiovascular outcomes.

Approach:

  • Meta-analysis of large randomized controlled trials (RCTs) on colchicine for cardiovascular outcomes.
  • Assessment of colchicine's effect on major adverse cardiovascular events (MACEs) and mortality.
  • Evaluation of potential biomarkers like C-reactive protein for treatment response.

Key Points:

  • Colchicine reduces recurrent MACE by 25% and is FDA-approved for cardiovascular disease treatment and prevention.
  • No significant survival benefit was observed; a non-significant increase in non-cardiovascular death risk was noted.
  • Under-representation of key populations in trials limits generalizability.
  • C-reactive protein shows promise as a biomarker to identify high-risk patients, but requires validation.

Conclusions:

  • Colchicine demonstrates potential in reducing MACE for atherosclerotic vascular disease.
  • The overall risk-benefit profile requires further investigation before widespread clinical adoption.
  • More large-scale, long-term trial data are essential for definitive conclusions on secondary prevention.